Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

## **Product Information**

Product ID C2900

CAS No. 1256580-46-7

**Chemical Name** 

Synonym CH 5424802, Alectinib

 $\textbf{Formula} \quad C_{30} H_{34} N_4 O_2$ Formula Wt. 482.62

**Melting Point** 

Purity ≥99%

Solubility DMSO 0.5 mg/mL warmed

(1.03 mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C Ship Temp Ambient

Description CH5424802 is an inhibitor of anaplastic lymphoma kinase (ALK) that displays anticancer chemotherapeutic and anti-metastatic

activities against WT and L1196M mutant ALK. This compound is in clinical trials as a potential treatment for various cancers. CH5424802 induces regression of non-small cell lung cancer (NSCLC) cell metastasis in the brain in vivo, increasing survival rates. This compound displays efficacy in subjects resistant to crizotanib.

## Bulk quanitites available upon request

Product ID	Size
C2900	1 mg
C2900	5 mg
C2900	10 mg

References Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged nonsmall-cell lung cancer. Expert Rev Respir Med. 2015 Feb 5:1-14. [Epub ahead of print]. PMID: 25652176.

> Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. PMID: 25205428.

Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014 Sep 1;351(2):215-21. PMID: 24887559.

Rossi A, Maione P, Sacco PC, et al. ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014 Aug;45 (2):499-508. PMID: 24889366.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.